The authors concluded that the evidence from these clinical trials measuring the effectiveness and safety of anti-VEGF, for use in treating proliferative diabetic retinopathy to achieve standard benefits, was of low or very low quality. The gene discussed is VEGFA; the disease is proliferative diabetic retinopathy.